Table 3.
Ibrutinib Based Regimens in MCL in R/R and Frontline Settings
| Study | Regimen | N | Phase | PFS (median follow-up in month) | ORR (CR) |
|---|---|---|---|---|---|
| R/R MCL Single Agent BTKi | |||||
| Wang 2013 [13, 14] | Ibr | 111 | II | 21% (24) | 67% (23%) |
| Dreyling 2016 [127] | Ibr vs. temsirolimus | 280 | III | 14.6 vs. 6.2 m (20)* | 81% (40%) |
| R/R MCL Combination Regimens | |||||
| Wang 2016 [84] | Ibr + R | 50 | II | 69% (15) 75% (12) |
88% (44%) |
| Tam 2018 [83] | Ibr + Ven | 24 | II | 43 m (48) | 71% (71%) |
| Jerkeman 2020 [82] | Ibr + Len + R | 50 | II | 18 m (40) 56.9% (12) |
76% (56%) |
| Lee 2021 [85] | Ibr + cirmtuzumab | 20 | I/II | NR (25) | 90% (35%) |
| Frontline MCL | |||||
| Wang 2019 [87] | Ibr + R induction prior to CIT | 131 | II | 82% (36) | 100% (88%) |
| Jain 2021 [88] | Ibr + R in elderly | 50 | II | NR* | 98% (60%) |
| Le Gouill 2021 [89] | Ibr + Ven + O | 15 | I | 74.5% (12) | 75% (67%) |
| Wang 2022 [90] | BR +/− Ibr | 523 | III | 80.6 vs. 52.9 (85)* | |
BR: Bendamustine/rituximab Ibr: Ibrutinib; R: rituximab; Ven: Venetoclax; Len: Lenalidomide; O: Obinutuzumab; NR: not reached; m: months
*
median progression free survival